Aegis Capital Corp.

IAC/InterActiveCorp. Is A Top SMID Idea For 2017

Aegis Capital Believes Valeant Pharmaceuticals' Bid For Allergan Is Looking More Promising

Aegis Capital Believes Seragon Deal Underscores Value In Medivation

Aegis Capital Believes Valeant Pharmaceuticals' Bid For Allergan Is Looking More Promising

Aegis Capital Believes Seragon Deal Underscores Value In Medivation

UPDATE: Aegis Capital Initiates Coverage on Evoke Pharma on Attractive Valuation

Aegis Capital Reiterates on TrovaGene Following In-Line Revenue, Below-Estimates EPS

UPDATE: Aegis Capital Initiates Coverage on Evoke Pharma on Attractive Valuation

|

Aegis Capital Reiterates on TrovaGene Following In-Line Revenue, Below-Estimates EPS

|

UPDATE: Aegis Capital Reiterates on Cancer Genetics Following Better-Than-Expected 3Q 2013 Financial Results

|

UPDATE: Aegis Capital Initiates Coverage on QLogic on Market Leader Position

|

Aegis Capital Corp. Recent News

UPDATE: Aegis Capital Reiterates on Synergy Pharmaceuticals on Approaching Clinical Catalysts

|

UPDATE: Aegis Capital Reiterates on Medivation Following In-Line 3Q 2013 Financial Results

|

UPDATE: Aegis Capital Reiterates on Stemline Therapeutics Ahead of ASH Annual Meeting

|

UPDATE: Aegis Capital Reiterates on TrovaGene Ahead of 3Q 2013 Earnings Report

|

UPDATE: Aegis Capital Reiterates on Inovio Pharmaceuticals Following Solid 3Q 2013 Results

|

UPDATE: Aegis Capital Reiterates on Navidea Biopharmaceuticals Following 3Q 2013 Earnings Report

|

Aegis Capital Reiterates on Sinovac Biotech Following Solid 3Q 2013 Financial Results

|

Aegis Capital Corp. Reiterates on Amarin Corporation plc After FDA Formally Rescinds Special Protocol Assessment

|

UPDATE: Aegis Capital Downgrades Amarin Following Negative Panel Vote on Vascepa

|

Aegis Capital Reiterates Buy on Amarin Corporation Following Release of Vascepa Briefing Documents

|

UPDATE: Aegis Capital Reiterates Buy Rating, Raises PT on Neuralstem

|

UPDATE: Aegis Capital Reiterates Buy Rating, Raises PT on China Biologic Products

|

UPDATE: Aegis Capital Initiates Coverage on Venaxis with Buy Rating, $6 PT

|

Aegis Capital Reiterates Buy Rating, $25 PT on Synergy Pharmaceuticals

|

Aegis Capital Reiterates Buy Rating, $25 PT on Synergy Pharmaceuticals

|

Aegis Capital Corp. Reiterates Buy Rating, $100 PT on Medivation

|

UPDATE: Aegis Capital Initiates Coverage on Sinovac Biotech with Hold Rating, $2.50 PT

|

UPDATE: Aegis Capital Initiates Coverage on TrovaGene with Buy Rating, $12 PT

|

UPDATE: Aegis Capital Initiates Coverage on China Cord Blood Corp. with Buy Rating, $5 PT

|

UPDATE: Aegis Capital Initiates Coverage on China Biologic Products with Buy Rating, $20 PT

|

UPDATE: Aegis Capital Corp. Initiates Coverage on Galena Biopharma with Buy Rating, $6 PT

|

UPDATE: Aegis Capital Initiates Coverage on Trius Therapeutics with Buy Rating, $15 PT

|